In the context of KRAS-driven pancreatic ductal adenocarcinoma with mutant KRAS, glutamine is pivotal both to induce cancer-promoting ROS production and to fuel antioxidant pathways, resulting in an increased homoeostatic ROS set point. The gene discussed is KRAS; the disease is cancer.